$40.91
0.05[0.12%]
At close: Apr 25
$40.91
0[0.00%]
After Hours: 4:00PM EDT
GSK Stock (NYSE:GSK), Analyst Ratings, Price Targets, Predictions
GSK PLC has a consensus price target of $18.4, established from looking at the 5 latest analyst ratings. The last 3 analyst ratings were released from Guggenheim, Morgan Stanley, and Jefferies on March 4, 2024, January 23, 2024, and January 3, 2024. With an average price target of $30.67 between Guggenheim, Morgan Stanley, and Jefferies, there's an implied -25.04% downside for GSK PLC from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
Morgan Stanley
Jefferies
DZ Bank
Barclays
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for GSK
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/04/2024 | GSK | Buy Now | GSK | $40.91 | — | Guggenheim | Seamus Fernandez | — | Upgrade | Neutral → Buy | Get Alert |
| 01/23/2024 | GSK | Buy Now | GSK | $40.91 | 7.55% | Morgan Stanley | Mark Purcell | → $44 | Initiates | → Equal-Weight | Get Alert |
| 01/03/2024 | GSK | Buy Now | GSK | $40.91 | 17.33% | Jefferies | Peter Welford | $38.5 → $48 | Upgrade | Hold → Buy | Get Alert |
| 02/11/2022 | GSK | Buy Now | GSK | $40.91 | — | DZ Bank | Elmar Kraus | — | Downgrade | Buy → Hold | Get Alert |
| 11/05/2021 | GSK | Buy Now | GlaxoSmithKline | $40.91 | — | Barclays | Emily Field | — | Upgrade | Underweight → Equal-Weight | Get Alert |
FAQ
What is the target price for GSK (GSK)?
The latest price target for GSK (NYSE: GSK) was reported by Guggenheim on March 4, 2024. The analyst firm set a price target for $0.00 expecting GSK to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GSK (GSK)?
The latest analyst rating for GSK (NYSE: GSK) was provided by Guggenheim, and GSK upgraded their buy rating.
When was the last upgrade for GSK (GSK)?
The last upgrade for GSK PLC happened on March 4, 2024 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for GSK PLC.
When was the last downgrade for GSK (GSK)?
The last downgrade for GSK PLC happened on February 11, 2022 when DZ Bank changed their price target from N/A to N/A for GSK PLC.
When is the next analyst rating going to be posted or updated for GSK (GSK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GSK, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GSK was filed on March 4, 2024 so you should expect the next rating to be made available sometime around March 4, 2025.
Is the Analyst Rating GSK (GSK) correct?
While ratings are subjective and will change, the latest GSK (GSK) rating was a upgraded with a price target of $0.00 to $0.00. The current price GSK (GSK) is trading at is $40.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.